Abstract
Objective: Ulcerative colitis (UC) is characterized by mucosal inflammation and ulceration of the large intestine. Emu Oil (EO) has been reported to protect the intestine against mucositis, NSAID-enteropathy, UC-associated colorectal cancer and acute UC. We aimed to determine whether EO could reduce the severity chronic UC in mice. Methods: Female C57BL/6 mice (n = 10/group) were orally administered (gavage) water (Groups 1–2) or EO (Groups 3: low dose-80 µl and 4: high dose-160 µl), thrice weekly. Group 1 mice consumed plain drinking water throughout the trial. Groups 2–4 mice underwent two cycles [each consisting of seven days dextran sulfate sodium (DSS; 2% w/v) and 14 days water], followed by a third DSS week. All mice were euthanized two days later (day 51). Bodyweight, disease activity index (DAI), burrowing activity, myeloperoxidase activity, crypt depth and histologically assessed damage severity were assessed. p <.05 was considered significant. Results: DSS decreased bodyweight and increased DAI compared to normal controls (p <.05), which was partially attenuated by both EO doses (p <.05). Burrowing activity was impaired in DSS-controls compared to normal controls (days 27 and 40); an effect prevented by both EO doses (p <.05). DSS increased colonic myeloperoxidase activity and crypt depth compared to controls (p <.05), with no significant EO effect. Moreover, DSS increased colonic damage severity compared to normal controls (p <.001). Importantly, both EO doses decreased distal colonic damage severity compared to DSS-controls (p <.001). Conclusions: Emu Oil attenuated clinically- and histologically-assessed disease severity in a mouse model of chronic UC. Emu Oil demonstrates promise as an adjunct to conventional treatment options for UC management.
| Original language | English |
|---|---|
| Pages (from-to) | 273-280 |
| Number of pages | 8 |
| Journal | Scandinavian Journal of Gastroenterology |
| Volume | 54 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 4 Mar 2019 |
Fingerprint
Cite this
}
Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis. / Safaeian, Romina; Howarth, Gordon S.; Lawrance, Ian C.; Trinder, Debbie; Mashtoub, Suzanne.
In: Scandinavian Journal of Gastroenterology, Vol. 54, No. 3, 04.03.2019, p. 273-280.Research output: Contribution to journal › Article
TY - JOUR
T1 - Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis
AU - Safaeian, Romina
AU - Howarth, Gordon S.
AU - Lawrance, Ian C.
AU - Trinder, Debbie
AU - Mashtoub, Suzanne
PY - 2019/3/4
Y1 - 2019/3/4
N2 - Objective: Ulcerative colitis (UC) is characterized by mucosal inflammation and ulceration of the large intestine. Emu Oil (EO) has been reported to protect the intestine against mucositis, NSAID-enteropathy, UC-associated colorectal cancer and acute UC. We aimed to determine whether EO could reduce the severity chronic UC in mice. Methods: Female C57BL/6 mice (n = 10/group) were orally administered (gavage) water (Groups 1–2) or EO (Groups 3: low dose-80 µl and 4: high dose-160 µl), thrice weekly. Group 1 mice consumed plain drinking water throughout the trial. Groups 2–4 mice underwent two cycles [each consisting of seven days dextran sulfate sodium (DSS; 2% w/v) and 14 days water], followed by a third DSS week. All mice were euthanized two days later (day 51). Bodyweight, disease activity index (DAI), burrowing activity, myeloperoxidase activity, crypt depth and histologically assessed damage severity were assessed. p <.05 was considered significant. Results: DSS decreased bodyweight and increased DAI compared to normal controls (p <.05), which was partially attenuated by both EO doses (p <.05). Burrowing activity was impaired in DSS-controls compared to normal controls (days 27 and 40); an effect prevented by both EO doses (p <.05). DSS increased colonic myeloperoxidase activity and crypt depth compared to controls (p <.05), with no significant EO effect. Moreover, DSS increased colonic damage severity compared to normal controls (p <.001). Importantly, both EO doses decreased distal colonic damage severity compared to DSS-controls (p <.001). Conclusions: Emu Oil attenuated clinically- and histologically-assessed disease severity in a mouse model of chronic UC. Emu Oil demonstrates promise as an adjunct to conventional treatment options for UC management.
AB - Objective: Ulcerative colitis (UC) is characterized by mucosal inflammation and ulceration of the large intestine. Emu Oil (EO) has been reported to protect the intestine against mucositis, NSAID-enteropathy, UC-associated colorectal cancer and acute UC. We aimed to determine whether EO could reduce the severity chronic UC in mice. Methods: Female C57BL/6 mice (n = 10/group) were orally administered (gavage) water (Groups 1–2) or EO (Groups 3: low dose-80 µl and 4: high dose-160 µl), thrice weekly. Group 1 mice consumed plain drinking water throughout the trial. Groups 2–4 mice underwent two cycles [each consisting of seven days dextran sulfate sodium (DSS; 2% w/v) and 14 days water], followed by a third DSS week. All mice were euthanized two days later (day 51). Bodyweight, disease activity index (DAI), burrowing activity, myeloperoxidase activity, crypt depth and histologically assessed damage severity were assessed. p <.05 was considered significant. Results: DSS decreased bodyweight and increased DAI compared to normal controls (p <.05), which was partially attenuated by both EO doses (p <.05). Burrowing activity was impaired in DSS-controls compared to normal controls (days 27 and 40); an effect prevented by both EO doses (p <.05). DSS increased colonic myeloperoxidase activity and crypt depth compared to controls (p <.05), with no significant EO effect. Moreover, DSS increased colonic damage severity compared to normal controls (p <.001). Importantly, both EO doses decreased distal colonic damage severity compared to DSS-controls (p <.001). Conclusions: Emu Oil attenuated clinically- and histologically-assessed disease severity in a mouse model of chronic UC. Emu Oil demonstrates promise as an adjunct to conventional treatment options for UC management.
KW - chronic
KW - Emu Oil
KW - inflammatory bowel disease
KW - mice
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85063266948&partnerID=8YFLogxK
U2 - 10.1080/00365521.2019.1581253
DO - 10.1080/00365521.2019.1581253
M3 - Article
VL - 54
SP - 273
EP - 280
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 3
ER -